Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases

Дата публикации: 03-07-2026 00:00:00

This prognostic study evaluates the association between circulating tumor DNA–defined molecular residual disease and survival outcomes and whether molecular residual disease status is associated with differential benefit from adjuvant chemotherapy in resected colorectal liver metastases.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Tumor Debulking Plus Chemotherapy for Multiorgan Metastatic Colorectal Cancer—Reply	0	6.33	18-08-2026
2	Liquid Biopsies for Cancer	0	8.31	10-08-2026
3	Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis	0	7	02-07-2026
4	Effect of Neoadjuvant Therapy on Postoperative Complications in Colorectal Cancer: A Multicenter Prospective Propensity-Matched Cohort Study	0	5	16-07-2026
5	Addition of High-Dose Vitamin D 3 to Standard Treatment for Metastatic Colorectal Cancer	0	13.41	03-08-2026
6	Race, Secondary Treatment, and Survival in Localized Prostate Cancer	0	5.24	21-07-2026
7	Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors	0	11.9	01-07-2026
8	Troponin Screening and Major Cardiovascular Adverse Events During ICI Therapy	0	7.02	21-07-2026
9	Federal Housing Assistance and Survival in Older Adults With NSCLC	0	8.64	30-07-2026
10	Temporal Trends in Lung Cancer Cases Diagnosed at Early Stage	0	5.63	01-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.